Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1811671
Transjugular Intrahepatic Portosystemic Shunt for the Management of Medically Refractory Chylous Ascites in Cirrhosis: A Single-Institution Retrospective Analysis
Abstract
We report our experience with using transjugular intrahepatic portosystemic shunt (TIPS) for the management of chylous ascites in cirrhotic patients. A total of eight patients were included in the final analysis. The primary outcome assessed was the resolution of ascites. Secondary outcomes, including hepatic encephalopathy (HE), sepsis, worsening of liver function, and transplant-free survival, were also evaluated. Three-month follow-up imaging showed resolution of ascites in all patients, except for one who had concurrent renal dysfunction. Two patients died 3 and 5 months after TIPS due to sepsis and multi-organ failure. The incidence of HE during the follow-up period was 25%. No patient experienced significant worsening of liver function in the early post-procedure phase. One patient received a transplant 9 months after TIPS. Mean transplant-free survival for the remaining patients was 19 months. In conclusion, TIPS is an effective treatment for managing chylous ascites in cirrhosis that is refractory to medical therapy.
Publication History
Article published online:
15 September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Rector Jr WG. Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 1984; 6 (04) 369-372
- 2 Berzigotti A, Magalotti D, Cocci C, Angeloni L, Pironi L, Zoli M. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report. Dig Liver Dis 2006; 38 (02) 138-142
- 3 Kikolski SG, Aryafar H, Rose SC, Roberts AC, Kinney TB. Transjugular intrahepatic portosystemic shunt for treatment of cirrhosis-related chylothorax and chylous ascites: single-institution retrospective experience. Cardiovasc Intervent Radiol 2013; 36 (04) 992-997
- 4 Tsauo J, Shin JH, Han K. et al. Transjugular intrahepatic portosystemic shunt for the treatment of chylothorax and chylous ascites in cirrhosis: a case report and systematic review of the literature. J Vasc Interv Radiol 2016; 27 (01) 112-116
- 5 Kinney TB, Ferrara SL, Miller FJ, Roberts AC, Hassanein T. Transjugular intrahepatic portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in a patient with cirrhosis. J Vasc Interv Radiol 2004; 15 (1, Pt 1): 85-89
- 6 de Vries GJ, Ryan BM, de Bièvre M, Driessen A, Stockbrugger RW, Koek GH. Cirrhosis related chylous ascites successfully treated with TIPS. Eur J Gastroenterol Hepatol 2005; 17 (04) 463-466
- 7 Baerlocher MO, Nikolic B, Sze DY. Adverse event classification: clarification and validation of the Society of Interventional Radiology Specialty-Specific System. J Vasc Interv Radiol 2023; 34 (01) 1-3
- 8 Liu CJ, Sun AX, Shi XY, Sun ZQ. Cirrhosis-related chylous ascites successfully treated with splenic artery embolization. J Vasc Interv Radiol 2016; 27 (11) 1739-1741
- 9 Fonio P, Discalzi A, Calandri M. et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification. Radiol Med 2017; 122 (09) 713-721